Collectively, Aur-A/FOXO3A/SKP2 axis can promote ccRCC cell progression and the combination of Aur-A inhibitor MLN8237 and SKP2 inhibitor SZL P1-41 shows a synergistic lethality in vivo and in vitro, indicating a potential new therapeutic strategy for ccRCC (Fig. 7D). This evidence concerns the gene FOXO3 and nonpapillary renal cell carcinoma.